Anti-IgE monoclonal antibody for allergic disease
& The idea of using anti-IgE antibodies as a potential therapy for allergic disease has previously been considered an attractive yet impossible approach. However, researchers from Genentech may have proved the seeptics wrong by developing a recombinant humanised anti-IgE monoclonal antibody, E25...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Barnes, Jo [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1995 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© Adis International Ltd 1995 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Inpharma weekly - Auckland : ADIS internat., 1975, 1000(1995), 1 vom: Aug., Seite 9-10 |
|---|---|
| Übergeordnetes Werk: |
volume:1000 ; year:1995 ; number:1 ; month:08 ; pages:9-10 |
| Links: |
|---|
| DOI / URN: |
10.2165/00128413-199510000-00015 |
|---|
| Katalog-ID: |
SPR036156523 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR036156523 | ||
| 003 | DE-627 | ||
| 005 | 20230519163556.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s1995 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2165/00128413-199510000-00015 |2 doi | |
| 035 | |a (DE-627)SPR036156523 | ||
| 035 | |a (SPR)00128413-199510000-00015-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Barnes, Jo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anti-IgE monoclonal antibody for allergic disease |
| 264 | 1 | |c 1995 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Adis International Ltd 1995 | ||
| 520 | |a & The idea of using anti-IgE antibodies as a potential therapy for allergic disease has previously been considered an attractive yet impossible approach. However, researchers from Genentech may have proved the seeptics wrong by developing a recombinant humanised anti-IgE monoclonal antibody, E25, that binds to and neutralises circulating IgE. Details of the clinical and preclinical experience with E25, as well as Genentech’s plans for further development with this agent, were presented at the International Symposium on Clinical Immunology [San Francisco, US; July 1995]. | ||
| 650 | 4 | |a Allergic Disease |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Clinical Immunology |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Preclinical Experience |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Induce Histamine Release |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Preclinical Efficacy Study |7 (dpeaa)DE-He213 | |
| 773 | 0 | 8 | |i Enthalten in |t Inpharma weekly |d Auckland : ADIS internat., 1975 |g 1000(1995), 1 vom: Aug., Seite 9-10 |w (DE-627)373977859 |w (DE-600)2127607-9 |x 2230-6056 |7 nnns |
| 773 | 1 | 8 | |g volume:1000 |g year:1995 |g number:1 |g month:08 |g pages:9-10 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.2165/00128413-199510000-00015 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_20 | ||
| 951 | |a AR | ||
| 952 | |d 1000 |j 1995 |e 1 |c 08 |h 9-10 | ||
| author_variant |
j b jb |
|---|---|
| matchkey_str |
article:22306056:1995----::nigmncoaatbdfrl |
| hierarchy_sort_str |
1995 |
| publishDate |
1995 |
| allfields |
10.2165/00128413-199510000-00015 doi (DE-627)SPR036156523 (SPR)00128413-199510000-00015-e DE-627 ger DE-627 rakwb eng Barnes, Jo verfasserin aut Anti-IgE monoclonal antibody for allergic disease 1995 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 1995 & The idea of using anti-IgE antibodies as a potential therapy for allergic disease has previously been considered an attractive yet impossible approach. However, researchers from Genentech may have proved the seeptics wrong by developing a recombinant humanised anti-IgE monoclonal antibody, E25, that binds to and neutralises circulating IgE. Details of the clinical and preclinical experience with E25, as well as Genentech’s plans for further development with this agent, were presented at the International Symposium on Clinical Immunology [San Francisco, US; July 1995]. Allergic Disease (dpeaa)DE-He213 Clinical Immunology (dpeaa)DE-He213 Preclinical Experience (dpeaa)DE-He213 Induce Histamine Release (dpeaa)DE-He213 Preclinical Efficacy Study (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1000(1995), 1 vom: Aug., Seite 9-10 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1000 year:1995 number:1 month:08 pages:9-10 https://dx.doi.org/10.2165/00128413-199510000-00015 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 AR 1000 1995 1 08 9-10 |
| spelling |
10.2165/00128413-199510000-00015 doi (DE-627)SPR036156523 (SPR)00128413-199510000-00015-e DE-627 ger DE-627 rakwb eng Barnes, Jo verfasserin aut Anti-IgE monoclonal antibody for allergic disease 1995 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 1995 & The idea of using anti-IgE antibodies as a potential therapy for allergic disease has previously been considered an attractive yet impossible approach. However, researchers from Genentech may have proved the seeptics wrong by developing a recombinant humanised anti-IgE monoclonal antibody, E25, that binds to and neutralises circulating IgE. Details of the clinical and preclinical experience with E25, as well as Genentech’s plans for further development with this agent, were presented at the International Symposium on Clinical Immunology [San Francisco, US; July 1995]. Allergic Disease (dpeaa)DE-He213 Clinical Immunology (dpeaa)DE-He213 Preclinical Experience (dpeaa)DE-He213 Induce Histamine Release (dpeaa)DE-He213 Preclinical Efficacy Study (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1000(1995), 1 vom: Aug., Seite 9-10 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1000 year:1995 number:1 month:08 pages:9-10 https://dx.doi.org/10.2165/00128413-199510000-00015 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 AR 1000 1995 1 08 9-10 |
| allfields_unstemmed |
10.2165/00128413-199510000-00015 doi (DE-627)SPR036156523 (SPR)00128413-199510000-00015-e DE-627 ger DE-627 rakwb eng Barnes, Jo verfasserin aut Anti-IgE monoclonal antibody for allergic disease 1995 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 1995 & The idea of using anti-IgE antibodies as a potential therapy for allergic disease has previously been considered an attractive yet impossible approach. However, researchers from Genentech may have proved the seeptics wrong by developing a recombinant humanised anti-IgE monoclonal antibody, E25, that binds to and neutralises circulating IgE. Details of the clinical and preclinical experience with E25, as well as Genentech’s plans for further development with this agent, were presented at the International Symposium on Clinical Immunology [San Francisco, US; July 1995]. Allergic Disease (dpeaa)DE-He213 Clinical Immunology (dpeaa)DE-He213 Preclinical Experience (dpeaa)DE-He213 Induce Histamine Release (dpeaa)DE-He213 Preclinical Efficacy Study (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1000(1995), 1 vom: Aug., Seite 9-10 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1000 year:1995 number:1 month:08 pages:9-10 https://dx.doi.org/10.2165/00128413-199510000-00015 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 AR 1000 1995 1 08 9-10 |
| allfieldsGer |
10.2165/00128413-199510000-00015 doi (DE-627)SPR036156523 (SPR)00128413-199510000-00015-e DE-627 ger DE-627 rakwb eng Barnes, Jo verfasserin aut Anti-IgE monoclonal antibody for allergic disease 1995 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 1995 & The idea of using anti-IgE antibodies as a potential therapy for allergic disease has previously been considered an attractive yet impossible approach. However, researchers from Genentech may have proved the seeptics wrong by developing a recombinant humanised anti-IgE monoclonal antibody, E25, that binds to and neutralises circulating IgE. Details of the clinical and preclinical experience with E25, as well as Genentech’s plans for further development with this agent, were presented at the International Symposium on Clinical Immunology [San Francisco, US; July 1995]. Allergic Disease (dpeaa)DE-He213 Clinical Immunology (dpeaa)DE-He213 Preclinical Experience (dpeaa)DE-He213 Induce Histamine Release (dpeaa)DE-He213 Preclinical Efficacy Study (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1000(1995), 1 vom: Aug., Seite 9-10 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1000 year:1995 number:1 month:08 pages:9-10 https://dx.doi.org/10.2165/00128413-199510000-00015 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 AR 1000 1995 1 08 9-10 |
| allfieldsSound |
10.2165/00128413-199510000-00015 doi (DE-627)SPR036156523 (SPR)00128413-199510000-00015-e DE-627 ger DE-627 rakwb eng Barnes, Jo verfasserin aut Anti-IgE monoclonal antibody for allergic disease 1995 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 1995 & The idea of using anti-IgE antibodies as a potential therapy for allergic disease has previously been considered an attractive yet impossible approach. However, researchers from Genentech may have proved the seeptics wrong by developing a recombinant humanised anti-IgE monoclonal antibody, E25, that binds to and neutralises circulating IgE. Details of the clinical and preclinical experience with E25, as well as Genentech’s plans for further development with this agent, were presented at the International Symposium on Clinical Immunology [San Francisco, US; July 1995]. Allergic Disease (dpeaa)DE-He213 Clinical Immunology (dpeaa)DE-He213 Preclinical Experience (dpeaa)DE-He213 Induce Histamine Release (dpeaa)DE-He213 Preclinical Efficacy Study (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1000(1995), 1 vom: Aug., Seite 9-10 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1000 year:1995 number:1 month:08 pages:9-10 https://dx.doi.org/10.2165/00128413-199510000-00015 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 AR 1000 1995 1 08 9-10 |
| language |
English |
| source |
Enthalten in Inpharma weekly 1000(1995), 1 vom: Aug., Seite 9-10 volume:1000 year:1995 number:1 month:08 pages:9-10 |
| sourceStr |
Enthalten in Inpharma weekly 1000(1995), 1 vom: Aug., Seite 9-10 volume:1000 year:1995 number:1 month:08 pages:9-10 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Allergic Disease Clinical Immunology Preclinical Experience Induce Histamine Release Preclinical Efficacy Study |
| isfreeaccess_bool |
false |
| container_title |
Inpharma weekly |
| authorswithroles_txt_mv |
Barnes, Jo @@aut@@ |
| publishDateDaySort_date |
1995-08-01T00:00:00Z |
| hierarchy_top_id |
373977859 |
| id |
SPR036156523 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR036156523</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519163556.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1995 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00128413-199510000-00015</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR036156523</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00128413-199510000-00015-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Barnes, Jo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Anti-IgE monoclonal antibody for allergic disease</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1995</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Adis International Ltd 1995</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">& The idea of using anti-IgE antibodies as a potential therapy for allergic disease has previously been considered an attractive yet impossible approach. However, researchers from Genentech may have proved the seeptics wrong by developing a recombinant humanised anti-IgE monoclonal antibody, E25, that binds to and neutralises circulating IgE. Details of the clinical and preclinical experience with E25, as well as Genentech’s plans for further development with this agent, were presented at the International Symposium on Clinical Immunology [San Francisco, US; July 1995].</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Allergic Disease</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Clinical Immunology</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Preclinical Experience</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Induce Histamine Release</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Preclinical Efficacy Study</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Inpharma weekly</subfield><subfield code="d">Auckland : ADIS internat., 1975</subfield><subfield code="g">1000(1995), 1 vom: Aug., Seite 9-10</subfield><subfield code="w">(DE-627)373977859</subfield><subfield code="w">(DE-600)2127607-9</subfield><subfield code="x">2230-6056</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1000</subfield><subfield code="g">year:1995</subfield><subfield code="g">number:1</subfield><subfield code="g">month:08</subfield><subfield code="g">pages:9-10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00128413-199510000-00015</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1000</subfield><subfield code="j">1995</subfield><subfield code="e">1</subfield><subfield code="c">08</subfield><subfield code="h">9-10</subfield></datafield></record></collection>
|
| author |
Barnes, Jo |
| spellingShingle |
Barnes, Jo misc Allergic Disease misc Clinical Immunology misc Preclinical Experience misc Induce Histamine Release misc Preclinical Efficacy Study Anti-IgE monoclonal antibody for allergic disease |
| authorStr |
Barnes, Jo |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)373977859 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
2230-6056 |
| topic_title |
Anti-IgE monoclonal antibody for allergic disease Allergic Disease (dpeaa)DE-He213 Clinical Immunology (dpeaa)DE-He213 Preclinical Experience (dpeaa)DE-He213 Induce Histamine Release (dpeaa)DE-He213 Preclinical Efficacy Study (dpeaa)DE-He213 |
| topic |
misc Allergic Disease misc Clinical Immunology misc Preclinical Experience misc Induce Histamine Release misc Preclinical Efficacy Study |
| topic_unstemmed |
misc Allergic Disease misc Clinical Immunology misc Preclinical Experience misc Induce Histamine Release misc Preclinical Efficacy Study |
| topic_browse |
misc Allergic Disease misc Clinical Immunology misc Preclinical Experience misc Induce Histamine Release misc Preclinical Efficacy Study |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Inpharma weekly |
| hierarchy_parent_id |
373977859 |
| hierarchy_top_title |
Inpharma weekly |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)373977859 (DE-600)2127607-9 |
| title |
Anti-IgE monoclonal antibody for allergic disease |
| ctrlnum |
(DE-627)SPR036156523 (SPR)00128413-199510000-00015-e |
| title_full |
Anti-IgE monoclonal antibody for allergic disease |
| author_sort |
Barnes, Jo |
| journal |
Inpharma weekly |
| journalStr |
Inpharma weekly |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1995 |
| contenttype_str_mv |
txt |
| container_start_page |
9 |
| author_browse |
Barnes, Jo |
| container_volume |
1000 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Barnes, Jo |
| doi_str_mv |
10.2165/00128413-199510000-00015 |
| title_sort |
anti-ige monoclonal antibody for allergic disease |
| title_auth |
Anti-IgE monoclonal antibody for allergic disease |
| abstract |
& The idea of using anti-IgE antibodies as a potential therapy for allergic disease has previously been considered an attractive yet impossible approach. However, researchers from Genentech may have proved the seeptics wrong by developing a recombinant humanised anti-IgE monoclonal antibody, E25, that binds to and neutralises circulating IgE. Details of the clinical and preclinical experience with E25, as well as Genentech’s plans for further development with this agent, were presented at the International Symposium on Clinical Immunology [San Francisco, US; July 1995]. © Adis International Ltd 1995 |
| abstractGer |
& The idea of using anti-IgE antibodies as a potential therapy for allergic disease has previously been considered an attractive yet impossible approach. However, researchers from Genentech may have proved the seeptics wrong by developing a recombinant humanised anti-IgE monoclonal antibody, E25, that binds to and neutralises circulating IgE. Details of the clinical and preclinical experience with E25, as well as Genentech’s plans for further development with this agent, were presented at the International Symposium on Clinical Immunology [San Francisco, US; July 1995]. © Adis International Ltd 1995 |
| abstract_unstemmed |
& The idea of using anti-IgE antibodies as a potential therapy for allergic disease has previously been considered an attractive yet impossible approach. However, researchers from Genentech may have proved the seeptics wrong by developing a recombinant humanised anti-IgE monoclonal antibody, E25, that binds to and neutralises circulating IgE. Details of the clinical and preclinical experience with E25, as well as Genentech’s plans for further development with this agent, were presented at the International Symposium on Clinical Immunology [San Francisco, US; July 1995]. © Adis International Ltd 1995 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 |
| container_issue |
1 |
| title_short |
Anti-IgE monoclonal antibody for allergic disease |
| url |
https://dx.doi.org/10.2165/00128413-199510000-00015 |
| remote_bool |
true |
| ppnlink |
373977859 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.2165/00128413-199510000-00015 |
| up_date |
2024-07-03T16:39:10.353Z |
| _version_ |
1803576672626147328 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR036156523</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519163556.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1995 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00128413-199510000-00015</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR036156523</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00128413-199510000-00015-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Barnes, Jo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Anti-IgE monoclonal antibody for allergic disease</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1995</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Adis International Ltd 1995</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">& The idea of using anti-IgE antibodies as a potential therapy for allergic disease has previously been considered an attractive yet impossible approach. However, researchers from Genentech may have proved the seeptics wrong by developing a recombinant humanised anti-IgE monoclonal antibody, E25, that binds to and neutralises circulating IgE. Details of the clinical and preclinical experience with E25, as well as Genentech’s plans for further development with this agent, were presented at the International Symposium on Clinical Immunology [San Francisco, US; July 1995].</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Allergic Disease</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Clinical Immunology</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Preclinical Experience</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Induce Histamine Release</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Preclinical Efficacy Study</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Inpharma weekly</subfield><subfield code="d">Auckland : ADIS internat., 1975</subfield><subfield code="g">1000(1995), 1 vom: Aug., Seite 9-10</subfield><subfield code="w">(DE-627)373977859</subfield><subfield code="w">(DE-600)2127607-9</subfield><subfield code="x">2230-6056</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1000</subfield><subfield code="g">year:1995</subfield><subfield code="g">number:1</subfield><subfield code="g">month:08</subfield><subfield code="g">pages:9-10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00128413-199510000-00015</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1000</subfield><subfield code="j">1995</subfield><subfield code="e">1</subfield><subfield code="c">08</subfield><subfield code="h">9-10</subfield></datafield></record></collection>
|
| score |
7.40178 |